Investor Presentaiton

Investor presentation Full year 2018 Slide 96 Global haemophilia market is growing by high-single digit Sales of recombinant coagulation factors NovoSevenⓇ Coagil VII® Recombinate®/Advate® KogenateⓇ/HelixateⓇ Strategic positioning of Novo Nordisk's haemophilia portfolio ObizurⓇ1 FeibaⓇ XynthaⓇ/RefactoⓇ Eloctate® NovoEight® bDKK 40 35 30 CAGR²: 3% CAGR²: 5% CAGR²: 9% N8-GP Idelvion® RixubisⓇ Novo Nordisk compound Status Strategic position AlprolixⓇ Benefix® NovoSevenⓇ Launched Maintain market leadership NovoEight® Launched Establish presence in a competitive market place Submitted³ Contribute to market conversion 25 20 Refixia®/ RebinynⓇ Approved 4 Contribute to new treatment paradigm 15 10 NovoThirteenⓇ Launched Launch first recombinant product 5 0 2013 2017 rFVIIa 2013 2017 2013 2017 rFVIII rFIX 1 ObizurⓇ only indicated for acquired haemophilia 2 CAGR for 5-year period Source: Company reported sales changing diabetes 3 Submitted in the USA, the EU and Japan 4 Refixia® is the global brand name and RebinynⓇ is the brand name in North America novo nordisk

View entire presentation